Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 217-223

  Polyzos, Aris ^a,b   Kalbakis, Kostas ^a   Kentepozidis, Nikolaos ^a   Giassas, Stylianos ^a   Kalykaki, Antonia ^a   Vardakis, Nikolaos ^a   Bozionelou, Vasiliki ^a   Saloustros, Emmanouel ^a   Kontopodis, Emmanouel ^a   Georgoulias, Vassilis ^a   Mavroudis, Dimitris ^a  

^a Hellenic Oncology Research Group HORG   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Bevacizumab; Metastatic breast cancer; Paclitaxel weekly; Salvage chemotherapy

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; DOCETAXEL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING DISORDER; BLOOD TOXICITY; BREAST CANCER; CANCER GROWTH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LIVER METASTASIS; LUNG METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; SKIN TOXICITY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79959623445     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1475-x     Document Type: Article

References (30)

1. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16:3439-3460 (Pubitemid 28481644)
2. Vogel CL, Azevedo S, Hilsenbeck S, East DR, Ayub J (1992) Survival after first recurrence of breast cancer. The Miami experience. Cancer 70:129-135
3. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6
4. Gasparini G (1999) Angiogenesis in breast cancer: role in biology, tumor progression, and prognosis. In: Bowcock A (ed) Breast cancer: molecular genetics, pathogenesis, and therapeutics. Humana Press, Torowa, NJ, pp 341-371
5. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669-676 (Pubitemid 36749215)
6. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969 (Pubitemid 27098025)
7. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
8. Drevs J (2008) VEGF and angiogenesis: implications for breast cancer therapy. Eur J Cancer 6:7-13
9. Cobleigh M, Miller K, Langmuir V (2001) Phase II dose escalation trial of Avastin (bevacizumab) in women with previously treated metastatic breast cancer. Breast Cancer Res Treat 69:301 (Pubitemid 33789215)
10. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23:792-799
11. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676
12. O'Shaughnessy J, Miles D, Gray RJ, Dieras V, Perez EA, Zon R, Cortes J, Zhou X, Phan S, Miller K (2010) A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol 28:15 (abstr 1005)
13. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992
14. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
15. National Cancer Institute (2003) Common toxicity criteria vs 3.0
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. JNCI Cancer Spectr 92:205-216 (Pubitemid 30099779)
17. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
18. Kaplan EL, Meier P (1959) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
19. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P (1995) Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159
20. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247
21. Greil R, Im Y, Pienkowski T, Waderly A, Awada A, Ciruelos E, Freitas-Junor R, Fumoleau P, Snuranpong V, Miles DW (2009) Quality of life among patients with locally recurrent or metastatic breast cancer: results from the phase III AVADO study of first-line bevacizumab plus docetaxel versus docetaxel plus placebo. EJC Suppl 7:266
22. Pivot X, Verma S, Thomssen C, Passos-Coelho JL, Latini L, Ciruelos E, Silva M, von Moos R, Chang H, Miles DW (2009) Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. J Clin Oncol, ASCO Annu Meet Proc 27(5S):1094
23. Robert NJ, Dieras V, Glaspy JA, Brufsky A, Bondareknko I, Lipatov O, Perez E, Yaderly D, Xhou X, Phan S (2009) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for firstline treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol, ASCO Annu Meet Proc 27(15S):1005
24. Perez EA, Hillman DW, Dentchev T, Le-Lindqwister NA, Geeraerts LH, Fitch TR, Liu H, Graham DL, Kahanic SP, Gross HM, Patel TA, Palmieri FM, Dueck AC (2010) North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Ann Oncol 21:269-274
25. Ardavanis A, Doufexis D, Kountourakis P, Malliou S, Karagiannis A, Kardara E, Sykoutri D, Charalampia M, Rigatos G (2009) Salvage therapy of pretreated advanced breast cancer with bevacizumab and paclitaxel every two weeks: a retrospective case review study. BMC Cancer 9:338
26. Brufsky A, Rivera RR, Hurvitz SA, Bondarenko IN, Smirnov V, Valero V, Rugo HS, Swamy R, Mu H, Perez EA (2010) Progression-free survival (PFS) in patient subgroups in RIBBON-2, a phase III trial of chemotherapy (chemo) plus or minus bevacizumab (BV) for second-line treatment of HER2-negative, locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 28:15
27. Dellapasqua S, Bertolini F, Bagnardi V, Campagnoli E, Scarano E, Torrisi R, Shaked Y, Mancuso P, Goldhirsch A, Rocca A, Pietri E, Colleoni M (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26:4899-4905
28. Garcia-Saenz JA, Martin M, Calles A, Bueno C, Rodriguez L, Bobokova J, Custodio A, Casado A, Diaz-Rubio E (2008) Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer. J Chemother 20:632-639
29. Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, Szucs TD (2009) Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 45:1397-1406
30. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678